verteporfin

Overview

Verteporfin is a benzoporphyrin derivative approved clinically for photodynamic therapy of age-related macular degeneration. As a research tool in oncology, it is widely used to inhibit YAP1/WWTR1 (TAZ) nuclear activity by disrupting YAP-TEAD protein–protein interactions. It has no approved oncology indication. unverified: true — not found in OncoKB canonical drug list; slug is corpus-derived.

Evidence in the corpus

• In gallbladder cancer (GBC) stroma, verteporfin abolished stiffness-induced (16 kPa) activation of cancer-associated fibroblasts (GFs), nuclear translocation of YAP1, and SEMA7A secretion; ChIP confirmed TEAD1 occupancy at the SEMA7A promoter was abrogated, functionally linking YAP-TEAD activity to the stiffness-driven SEMA7A/ITGB1/AKT/p300 paracrine cascade that promotes GBC invasion and EMT PMID:24997986.

Resistance mechanisms

Cancer types (linked)

• GBC

Sources

This page was processed by entity-page-writer on 2026-05-11.